StefanSchneider

Partner

München + 49.89.20.60.42.200

Connect

Share

Stefan Schneider ist ein Private Equity und Venture Capital Anwalt mit mehr als 15 Jahren Erfahrung in der Beratung von Investoren, Unternehmen und Managern bei komplexen nationalen und multinationalen Transaktionen. Er berät und verhandelt bei Übernahmen und Minderheitsbeteiligungen, Finanzierungsrunden in der Anfangs- und Endphase, Fusionen, Veräußerungen, Ausgliederungen, Aktionärsverträgen, Management Equity Programmen und Unternehmensreorganisationen.

Stefan beriet kürzlich über die Beteiligung von Alliance Ventures an The Mobility House AG, Eurazeo Growth's und Sofina's Beteiligung an adjust, Cardinal Health's 6,1 Milliarden Dollar Übernahme des Patienten-Produktportfolios von Medtronic, Materion's 30 Millionen Euro Übernahme der Hochleistungs-Materialsparte von Heraeus, Heilind's Übernahme der MPS-Gruppe und bei einer breiten Palette von Akquisitionen und Verkäufen durch Findos Investors. Im Bereich des Early-Stage-Investments beriet Stefan btov Partners bei seinen Investitionen in Cybus und Synfioo, Hi Inovs Beteiligung an Styla, einem Konsortium aus Wellington, Andera (ehemals EdRIP) und BioMed Partners, bei ihrer Beteiligung an Tricares, Keep Nation's Beteiligung an der Trademob GmbH und bei Seventures Beteiligungen an Testbirds und vonAtoB sowie bei Investitionen in und anschließendem Verkauf von Tradoria. Darüber hinaus berät er Wachstumsunternehmen in gesellschafts- und handelsrechtlichen Angelegenheiten.


Bevor er im Mai 2009 zu Jones Day kam, arbeitete Stefan mehr als vier Jahre lang in den Büros München und New York einer großen US-Kanzlei. Er ist Mitglied der Rechtsanwaltskammer München und im Deutschen Anwaltverein und dessen Arbeitskreis Kanzleimanagement.

Erfahrung

  • Stellex completes buyout of David Brown Santasalo GroupJones Day advised Stellex Capital Management LLC on its buyout of DB Santasalo S.à r.l from N4 Partners.
  • Tikehau Capital leads €13 million Series A funding of Build38 GmbHJones Day advised Tikehau Capital as lead investor in the €13 million Series A financing of Build38 GmbH, a leading provider of mobile application protection solutions that combine AI-powered threat intelligence and the strongest app shielding technology, with subsidiaries in Spain and Singapore.
  • Tikehau Capital leads Series B financing of VMRayJones Day advised Tikehau Ace Capital in leading alongside NRW.Bank and Gründerfonds Ruhr the Series B financing of VMRay, a global player in advanced threat detection and analysis that offers solutions for enterprises, governmental organizations, and MDRs to detect and analyze the most challenging malware and phishing threats.
  • Aurelius acquires three European paper mills from Sappi Limited in complex pan-European carve-out transactionJones Day is advising Aurelius in the acquisition of three European paper mills from Sappi Limited.
  • FleetCor acquires PlugsurfingJones Day advised FleetCor Technologies, Inc. in the acquisition of Plugsurfing, a leading European electric vehicle (EV) software and network provider.
  • ArchiMed acquires PlasmidFactoryJones Day advised ArchiMed, a leading trans-atlantic private equity healthcare specialist, on its acquisition of PlasmidFactory, a globally renowned high-quality producer of plasmid DNA with strong research capabilities, from IP due diligence to structuring of acquisition and rollover re-investment.
  • Portage Ventures (Sagard) leads $15 million Series A funding round of getquinJones Day represented Portage Ventures (Sagard), with participation from Horizons Ventures, embedded/capital and sino AG and angel investors such as N26 founder Maximilian Tayenthal and Scalable Capital founder Erik Podzuweit, in the $15 million Series A financing round of getquin, a social network for discussing and analyzing stocks, cryptocurrencies, and other investment opportunities.
  • CDPQ participates in record investment in Hy2genJones Day advised Caisse de dépôt et placement du Québec (CDPQ) on its participation in the record €200 million investment in green hydrogen pioneer Hy2gen AG, the world’s largest private investment in green hydrogen to date.
  • Aurelius sells remaining Office Depot Europe business to strategic buyer RAJA GroupJones Day advised AURELIUS Equity Opportunities in the sale of Office Depot Europe, which includes the remaining Viking and Office Depot Europe activities to strategic buyer RAJA Group.
  • Alliance Ventures invests in The Mobility House AGJones Day advised Alliance Ventures, the strategic venture capital arm of Renault-Nissan-Mitsubishi, in connection with its Series C investment in The Mobility House AG, a technology company that provides a platform for integrating vehicle batteries into power grids using intelligent charging, energy and storage solutions.
  • ArchiMed acquires Cube Biotech GmbHJones Day advised ArchiMed, a leading Trans-Atlantic private equity healthcare specialist, on its acquisition of Cube Biotech GmbH, a leading provider of expression, purification, and crystallization services and products for membrane proteins.
  • Cardinal Health sells its Cordis business to Hellman & Friedman for approximately $1 billionJones Day advised Cardinal Health in connection with the divestiture of its Cordis business to Hellman & Friedman for approximately $1 billion.
  • EMERAM Capital Partners sells portfolio company MEONA to Trill ImpactJones Day represented EMERAM Capital Partners GmbH, one of the leading investment companies for medium-sized companies in the German-speaking region, in the sale of its portfolio company MEONA, an innovation leader for clinical software, to the private equity firm, Trill Impact.
  • Wellington Partners, MIG GmbH & Co. Fonds 16, and Salvia GmbH invest €15 million in growth financing of Creative BalloonsJones Day represented Wellington Partners Life Sciences V, a leading European Venture Capital firm investing in early- and growth-stage Life Science companies, together with MIG GmbH & Co. Fonds 16 and Salvia GmbH, in connection with their €15 million growth investment in Creative Balloons GmbH, a specialist in researching and developing ultra-thin polyurethane (PUR) balloons for medical device applications, namely catheter manufacturing.
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to TolmarJones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited.
  • Astellas transfers DIFICLIR in Europe, Middle East, Africa, and selected CIS to Swiss Tillotts Pharma AG for €109 millionJones Day advised Astellas Pharma Europe Ltd. on the sale of distribution rights to the product "DIFICLIR" in Europe, Middle East, Africa, and selected Commonwealth of Independent States (CIS) countries to Swiss Tillotts Pharma AG for €109 million.
  • Materion acquires Optics Balzers, AG for $160 millionJones Day advised Materion Corporation, a global supplier of highly engineered advanced enabling materials, in its $160 million acquisition of Optics Balzers, AG, an industry leader in thin film optical coatings.
  • Rising Point Capital acquires Conco HoldingsJones Day advised Rising Point Capital, LLC in its acquisition of Conco Holdings, a provider of low-pressure, mechanical heat exchanger tube cleaning and non-destructive testing services.
  • EPH buys Nhow hotelJones Day advised Eastern Property Holdings (EPH), which is listed on the Swiss stock exchange, in the acquisition of the shares of the owner of Nhow Hotel in Berlin-Friedrichshain, a Berlin design hotel with 304 rooms and a total area of 20,000 square meters.
  • StepStone Group forms joint venture with ActivumJones Day advised StepStone Group LP on the formation of a joint venture with Activum SG, an investor in European real estate related sectors, in connection with its investment in four residential and commercial real estate assets located in Spain and Germany.
    •

    February 2023 Alert

    Better Together: U.S. and EU Enter Artificial Intelligence Collaboration Agreement

    April 2021 Commentary

    Regulating Artificial Intelligence: European Commission Launches Proposals

    April 2020 Commentary

    IP Protection of Artificial Intelligence in Europe: Tailor-Made Solutions Required

    October 2018 Commentary

    Game Changer for Cryptocurrency in Germany? Court Holds No License Required to Trade Bitcoins

    October 2018 Commentary

    ICOs and Token Regulation from a German Perspective

    Weitere Veröffentlichungen

    • October 2009
      Mehr Rechtssicherheit für Wandelanleihen, VentureCapital Magazin

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.